Chronic inflammatory enteropathy (CIE) in dogs involves a heterogeneous group of intestinal etiopathogenesis arising from complex interactions among diet, the intestinal microbiota, genetic susceptibility, and altered mucosal immune responses. There are several phenotypes within the CIE spectrum, classified by the dog’s response to treatment; however, protein-losing enteropathy (PLE) and granulomatous colitis are distinct subtypes of CIE with different pathophysiological mechanisms. As CIE is a diagnosis of exclusion, a thorough history and diagnostic evaluation are essential to accurate and complete treatment recommendations for that pet. CIE can be further categorized as food-responsive enteropathy (FRE or CIE-FR), immunosuppressant-responsive enteropathy (IRE or CIE-IR), non-responsive or refractory enteropathy (NRE or CIE-NR), and, more recently, microbiota-related modulation-responsive enteropathy (MrMRE).1,2 Similarly, PLE is subclassified as food- or dietary-responsive PLE, immunosuppressant-responsive PLE, or nonresponsive PLE.1 Although biopsies are helpful in investigating certain infectious diseases, the type of inflammation present (e.g., granulomatous inflammation, eosinophilic CIE, etc.), lymphatic disturbances, bacterial identification and antibiotic susceptibility profiles, and infiltrative alimentary neoplasia, this modality does not indicate what phenotype the dog will have. As such, it is realistic to follow a stepwise therapeutic approach for CIE in dogs that are otherwise hemodynamically stable. Dietary modification Dietary modification is the cornerstone treatment of CIE in dogs, as 38-89 percent of dogs with CIE, with and without hypoproteinemia, fall into the category of FRE.3 Dogs with CIE can respond to a variety of macronutrient manipulations, including highly digestible, hydrolyzed protein (animal-based vs. soy-based), limited ingredient, novel protein, elemental protein, fat-restricted or ultra-low fat-restricted, fiber-responsive, fresh commercial, or home-cooked diet.13 Depending on the dog’s historical clinical response to dietary trials, it is reasonable to consider a hydrolyzed protein diet initially for management of their CIE, as a 64-89 percent remission rate has been reported in referral practice with this type of diet.1 The most significant clinical improvements are seen within two weeks of an appropriate dietary change, although it may take up to three or more dietary changes before a successful response is seen in some dogs.4 For dogs with PLE and without a definitive etiology, a highly digestible, low-fat diet (dietary fat restriction < 30 g fat/Mcal ME; ideally < 26 g fat/Mcal ME) with adequate protein content is prioritized, although a hypoallergenic diet can be pursued if concurrent CIE is present, histopathological or clinical. A slightly higher dietary fat percentage could be considered if the proportion of medium-chain triglycerides exceeds that of long-chain triglycerides, as the latter are transported and ultimately contribute to the pathophysiology of PLE.5 In refractory PLE or marked intestinal lymphangiectasia cases, an ultra-low-fat diet (dietary fat < 15 g fat/Mcal ME) could be considered, although involvement with a board-certified veterinary nutritionist is strongly recommended to balance the essential fatty acids deficiency.6 Antibiotics If ≥ 3 adequately performed dietary trials fail to reduce or eliminate clinical signs associated with CIE, then consideration of treatments modulating the gut microbiome should be explored. An endoscopy (esophagogastroduodenoscopy or ileocolonoscopy) with biopsy can also be recommended at this stage prior to starting additional therapeutics. Antibiotics (e.g., metronidazole, tylosin, oxytetracycline, rifampin) have historically been utilized for immediate symptomatic relief and concurrent episodic treatment for CIE. However, several studies have reported short relapse rates after antibiotic discontinuation and substantial long-lasting intestinal dysbiosis.7-9 Diagnosis of intestinal parasites, infectious diseases, or granulomatous colitis/ileocolitis warrants antibiotic administration, although antimicrobial stewardship aims to start with one or a combination of prebiotics, probiotics, synbiotics, or fecal microbiota transplantation (FMT).1 Synbiotics The use of pre-, pro-, and synbiotics in dogs with CIE has variable clinical efficacy and is typically used as adjunctive treatment to diet or immunosuppressive therapy. The use of Saccharomyces boulardii as a probiotic has been reported to improve the clinical activity, fecal consistency, and body condition score in dogs with and without hypoproteinemia.10 Additionally, an 8-strain probiotic was shown to increase mucosal expression of tight junctions, thus improving intestinal barrier function in dogs with CIE.11 Synbiotics have not been shown to consistently produce clinical efficacy in studies thus far, although synbiotic-treated dogs were noted to have decreased fecal calprotectin and serum CRP concentrations, with favorable changes in gut mucosal bacteria.1 Prebiotics play a vital role in balancing intestinal microbiota, reducing the probability of pathogen adhesion and invasion, and enhancing intestinal barrier function by helping to regulate the innate immune response.12 The use of FMT in both acute and chronic gastroenteropathies has been explored with variable clinical responses. Several techniques are available for FMT administration, including fresh or fresh frozen fecal slurries (Figure 1) delivered through a colonic retention enema (Figure 2), feeding tube (e.g., nasogastric, esophagostomy, percutaneous endoscopy gastrostomy, gastrostomy tubes), or endoscopy (Figure 3), or oral capsules (fresh frozen (Figure 4) lyophilized capsules, freeze dried).13 While several studies showed no difference in treatment efficacy of dogs with CIE, others documented improved canine chronic enteropathy activity index (CCEAI) scores in 86 percent and 74 percent of dogs receiving a single FMT or freeze-dried oral FMT capsule, respectively.1 As there are many variables that play a role in case selection, healthy fecal donor status, number of FMTs needed, and administration technique, clinical response is unpredictable and may require an alternative fecal donor, additional FMT administration, or a different treatment modality altogether to achieve clinical improvement or remission. Regardless, it seems reasonable to consider FMT as a useful adjunctive treatment for poorly responsive dogs with CIE. Figure 1. Veterinary assistant Makayla Hansen preparing to administer a fresh fecal slurry in a 60 mL Luer Lock syringe. Photo courtesy Anna Panyutin Figure 2. A colonic retention enema performed in a cat using a premixed slurry of fresh feces from a healthy feline donor. Photo courtesy Anna Panyutin Immunomodulatory therapy A diagnosis of idiopathic CIE is typically relied upon through intestinal biopsies, along with incomplete clinical remission to multiple thorough dietary trials and microbiota-modulating therapeutics. Obtaining a biopsy may not always be feasible due to cost restraints, resources, or patient comorbidities precluding general anesthesia. As such, initiation of immunomodulatory therapy without a definitive diagnosis might be needed, especially if the patient’s lack of appetite or deteriorating clinical score fails does not permit a complete dietary trial.1 Pet owners should be informed of adverse effects associated with corticosteroids and/or secondary immunosuppressive medications, especially if an infectious or neoplastic etiology has not been ruled out. Dogs with suspected CIE are most commonly started on prednisone or prednisolone at an induction dose of 1-2 mg/kg/day (no more than 40 mg/m2 for dogs >25 kg) for two to three weeks or budesonide 3 mg/m2 PO q24hr for three to four weeks.9 If complete or at least partial clinical remission is achieved, a dose reduction of 25 percent every three to four weeks is typically performed. Should the dog’s clinical signs relapse on a lower dose of corticosteroids, then secondary immunosuppressive medications (e.g., cyclosporine, chlorambucil) could be considered. Figure 3. Endoscopic administration of a canine donor fecal slurry instilled directly into the duodenum of a dog with CIE. Photo courtesy Kasey Mabry Figure 4. AmendPet’s FMT processing device offers a standardized and convenientprocessing of a stool sample into delayed release oral capsules. Photo courtesy AmendPet Other options As many dogs with CIE do have documented hypocobalaminemia, parenteral (cyanocobalamin or hydroxocobalamin) or enteral (cyanocobalamin) vitamin B12 supplementation can be considered.14 Folate therapy is generally not needed unless a severe deficiency is documented, at which point a four-week course of 200 mcg (dogs < 20kg body weight) or 400 mcg (larger dogs > 20 kg body weight) is generally recommended.15 Anticoagulant therapy (e.g., clopidogrel 2-3 mg/kg PO q24hr) can be considered in patients with hypoalbuminemia, with discontinuation consideration once their serum albumin level is > 2.5 g/dL. Anti-nausea support (maropitant 2 mg/kg PO q24hr, ondansetron 0.3-1 mg/kg PO q8-12hr, metoclopramide 0.5 mg/kg 0.2-0.5 mg/kg PO q6-8hr), fluid therapy (subcutaneous, intravenous), and appetite stimulants (capromorelin 3 mg/kg PO q24hr, mirtazapine 0.5-1.3 mg/kg PO q24hr not to exceed 30mg/dog PO q24hr, cyproheptadine 0.2 mg/kg PO q12-24hr) should be considered supportively, as relapse can occur. Is it working? Clinical response can be measured objectively through several measures, including utilization of the canine inflammatory bowel disease activity index (CIBDAI) or CCECAI, with the following guidelines: complete remission as >75 percent reduction, partial response as 25 -75 percent reduction, and no response as <25 percent reduction. Alternatively, at least a 50 percent response rate is sufficient to classify a dog’s treatment as responsive, whereas a <50 percent response rate is classified as non-responsive. Serum albumin may normalize in dogs with PLE, although practically a serum albumin >2.5 g/dL is considered acceptable if their clinical signs are in remission.1 Periodic complete blood counts, biochemistry panels, and urinalysis should be performed on all dogs with CIE, although more frequent monitoring (every one to three months initially) are advised in dogs receiving immunomodulatory agents. Final thoughts Relapses can occur in dogs with CIE, particularly when there is an inappropriate diet change, dietary indiscretion, co-morbid complications affecting gut health (i.e., acute gut injury secondary to extra-GI disease), intestinal parasitism, among other reasons. It is important to obtain an accurate history to streamline your differential diagnoses and recommend appropriate diagnostic tests based on current history and physical exam findings. Repeating diagnostic tests, even if they have been historically normal, may be needed. Reintroducing historically failed therapeutics could be useful for the current issue, and implementing a novel therapeutic approach might have both short- and long-term clinical utility. Don’t be afraid to trial a new diet, as adverse food reactions can arise through multiple mechanisms. Microbial manipulation and new diet formulations will continue to evolve over the coming years, so it is important to keep an open mind and familiarize yourself with novel approaches that are likely to offer additive benefits without the need for lifelong immunomodulatory therapy. Kasey Mabry, DVM, MS, DACVIM (SAIM), is a small animal internal medicine specialist at South Carolina Veterinary Specialists and Emergency Care in Columbia, S.C. Dr. Mabry completed her small animal internal medicine residency and dual master’s degree in Comparative Biomedical Sciences at The University of Georgia. During this time, Mabry developed an interest in immune-mediated, gastrointestinal, and hepatobiliary diseases, with a strong research focus on canine acute gastrointestinal injury secondary to critical illness and exercise (canine athletes). She currently serves as the Internal Medicine Specialty director of Thrive Pet Healthcare, where she is actively involved in mentoring and teaching. References Heilmann R, Jergens A, Kathrani A, al. e. ACVIM-endorsed statement: consensus statement and systematic review on guidelines for the diagnosis and treatment of chronic inflammatory enteropathy in dogs. J Vet Intern Med. 2026;40(1) Dupouy-Manescau N, Meric T, Senecat O, et al. Updating the Classification of Chronic Inflammatory Enteropathies in Dogs. Animals (Basel). Feb 21 2024;14(5)doi:10.3390/ani14050681 Nagata N, Ohta H, Yokoyama N, al. e. Clinical characteristics of dogs with food-responsive protein-losing enteropathy. J Vet Intern Med. 2020;34(2):659-668. Wang S, Martins R, Sullivan M, al. e. Diet-induced remission in chronic enteropathy is associated with altered microbial community structure and synthesis of secondary bile acids. Microbiome. 2019;7:126. Willard M. Canine protein losing enteropathies. Israel J Vet Med. 2015;70(3):17-20. Jablonski S. Pathophysiology, diagnosis, and management of canine intestinal lymphangiectasia: a comparative review. Animals (Basel). 2022;12(20):2791. Allenspach K, Culverwell C, Chan D. Long-term outcome in dogs with chronic enteropathies: 203 cases. Vet Rec. Apr 9 2016;178(15):368. doi:10.1136/vr.103557 Kilpinem S, Spillmann T, Syrja P, Skrzypczak T, Louhelainen M, Westermarck E. Effect of tylosin on dogs with suspected tylosin-responsive diarrhea: a placebo-controlled, randomized, double-blinded, prospective clinical trial. Acta Vet Scan. 2011;53:26. Jergens AE, Crandell J, Morrison JA, et al. Comparison of oral prednisone and prednisone combined with metronidazole for induction therapy of canine inflammatory bowel disease: a randomized-controlled trial. J Vet Intern Med. Mar-Apr 2010;24(2):269-77. doi:10.1111/j.1939-1676.2009.0447.x D'Angelo S, Fracassi F, Bresciana F, al. e. Effect of Saccharomyces boulardii in dogs with chronic enteropathies: double-blinded, placebo-controlled study. Vet Rec. 2018;182(9):258. White R, Atherly T, Guard B, al. e. Randomized, controlled trial evaluating the effect of multi-strain probiotic on the mucosal microbiota in canine idiopathic inflammatory bowel disease. Gut Microbes. 2017;8(5):451-466. Xia J, Cui Y, Guo Y, Liu Y, Deng B, Han S. The Function of Probiotics and Prebiotics on Canine Intestinal Health and Their Evaluation Criteria. Microorganisms. 2024;12:1248. Winston J, Suchodolski J, Gaschen F, al e. Clinical Guidelines for Fecal Microbiota Transplantation in Companion Animals. Advances in Small Animal Care. 2024;5:79-107. Toresson L, Steiner J, Spodsberg E, al. e. Effects of oral versus parenteral cobalamin supplementation on methylmalonic acid and homocysteine concentrations in dogs with chronic enteropathies and low cobalamin concentrations. Vet J. 2019;243:8-14. Ullal T, Marks S, Huebner S, Taylor S, Shelley C. Association of folate concentrations with clinical signs and laboratory markers of chronic enteropathy in dogs. J Vet Intern Med. 2023;37:455-464.